Skip to main content
Log in

Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages

  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Auranofin (AF), a gold compound, is an orally active therapeutic agent used to treat rheumatoid arthritis (RA), a self-perpetuating inflammatory disease. RA is characterized by autoimmune-mediated proliferation of synovial cells that leads to inflammation, pain, and swelling in most major joints. However, the mechanism as to how AF relieves RA symptoms has not been fully elucidated. The object of this study was to examine the ability of AF to immunomodulate macrophages as antigen presenting cells (APCs). Macrophages are recognized as playing an important role in the pathogenesis of RA, in that there is a relative abundance of macrophage-derived cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in rheumatoid synovium. In this work, we tested whether AF (2.5–20 mM) could inhibit inflammatory activity in the macrophage cell line RAW 264.7. AF decreased production of nitric oxide (NO) and the pro-inflammatory cytokines, TNF-α, IL-1β and IL-6 in macrophages. Furthermore, AF inhibited cyclooxygenase-2 (COX-2)-dependent prostaglandin E2 (PGE2) production in a concentration-dependent manner. In conclusion, these findings may provide an explanation for the clinical effects of AF in patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Arend, W. P. and Dayer, J. M., Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum., 33, 305–315 (1990).

    Article  PubMed  CAS  Google Scholar 

  • Ben-Av, P., Crofford, L. J., Wilder, R. L., and Hla., T., Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS. Lett., 372, 83–87 (1995).

    Article  PubMed  CAS  Google Scholar 

  • Bogdan, C., Nitric oxide and the immune response. Nat Immunol., 2, 907–916 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Bondeson, J. and Sundler, R., Antirheumatic gold compounds and penicillamine enhance protein kinase C-mediated activation of the arachidonate-mobilizing phospholipase A2 in mouse macrophages. J. Leukoc Bio., 54, 329–335 (1993).

    CAS  Google Scholar 

  • Bondeson, J. and Sundler, R., Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Biochem Pharmacol., 50, 1753–1759 (1995).

    Article  PubMed  CAS  Google Scholar 

  • Borg, G., Allander, E., Lund, B., Berg, E., Brodin, U., Pettersson, H., and Trang, L., Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J. Rheumatol., 15, 1747–1754 (1998).

    Google Scholar 

  • Borghaei, R. C., Rawlings, P. L. Jr., and Mochan, E., Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum., 41, 1398–1406 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Chenevier-Gobeaux, C., Morin-Robinet, S., Lemarechal, H., Poiraudeau, S., Ekindjian, J. C., and Borderie, D., Effects of pro-and anti-inflammatory cytokines and nitric oxide donors on hyaluronic acid synthesis by synovial cells from patients with rheumatoid arthritis. Clin. Sci., 107, 291–296 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Coker, R. K. and Laurent, G. J., Pulmonary fibrosis: cytokines in the balance. Eur. Respir. J., 11, 1218–1221 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Crofford, L. J., Wilder, R. L., Ristimaki, A. P., Sano, H., Remmers, E. F., Epps, H. R., and Hla, T., Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J. Clin Invest., 93, 1095–1101 (1994).

    Article  PubMed  CAS  Google Scholar 

  • Cush, J. J. and Lipsky, P. E., Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum., 31, 1230–1238 (1988).

    Article  PubMed  CAS  Google Scholar 

  • Davis, P., Johnston, C., Miller, C. L., and Wong, K., Effects of gold compounds on the function of phagocytic cells. II. Inhibition of superoxide radical generation by tripeptide-activated polymorphonuclear leukocytes. Arthritis Rheum., 26, 82–86 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Dechanet, J., Briolay, J., Rissoan, M. C., Chomarat, P., Galizzi, J. P., Banchereau, J., and Miossec, P., IL-4 inhibits growth factor-stimulated rheumatoid synoviocyte proliferation by blocking the early phases of the cell cycle. J. Immunol., 151, 4908–4917 (1993).

    PubMed  CAS  Google Scholar 

  • Dimartino, M. J. and Walz, D. T., Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent. Inflammation., 2, 131–142 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Elmgreen, J., Ahnfelt-Ronne, I., and Nielsen, O. H., Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway. Ann Rheum Dis., 48, 134–138 (1989).

    Article  PubMed  CAS  Google Scholar 

  • Feldmann, M., Brennan, F. M., and Maini, R. N., Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol., 14, 397–440 (1997).

    Article  Google Scholar 

  • Firestein, G. S., Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis. Rheum., 39, 1781–1790 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto, K., Whitehurst, CE., Matsubara, T., Hirohata, K., and Lipsky, P. E., Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase. C. J. Clin Invest., 89, 1839–1848 (1992).

    Article  CAS  Google Scholar 

  • Hashimoto, K., Whitehurst, C. E., and Lipsky, P. E., Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. J Rheumatol., 21, 1020–1026 (1994).

    PubMed  CAS  Google Scholar 

  • Hirohata, S., Inhibition of human B cell activation by gold compounds. Clin Immunol Immunopathol., 81, 175–181 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Hla, T., Neilson, K., Human cyclooxygenase-2 cDNA. Proc Natl Acad Sc. U.S.A., 89, 7384–7388 (1992).

    Article  CAS  Google Scholar 

  • Isomaki, P. and Punnonen, J., Pro-and anti-inflammatory cytokines in rheumatoid arthritis. Ann. Med., 29, 499–507 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Janossy, G., Panayi, G., Duke, O., Bofill, M., Poulter, L. W., and Goldstein, G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet., 17, 839–842 (1997).

    Google Scholar 

  • Jeon, K. I., Byun, M. S., and Jue, D. M., Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp. Mol. Med., 35, 61–66 (2003).

    PubMed  CAS  Google Scholar 

  • Jeon, K. I., Jeong, J. Y., and Jue, D. M., Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J. Immunol., 164, 5981–5989 (2000).

    PubMed  CAS  Google Scholar 

  • Klaushofer, K., Hoffmann, O., Horandner, H., Karasegh, S., Fratzl-Zelman, N., Leis, H. J., Gleispach, H., Koller, K., and Peterlik, M., Effect of auranofin on resorption, prostaglandin synthesis and ultra structure of bone cells in cultured mouse calvaria. J. Rheumatol., 16, 749–756 (1989).

    PubMed  CAS  Google Scholar 

  • Lee, D. M., Weinblatt, M. E., Rheumatoid arthritis. Lancet., 358, 903–911 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Libby, P., Ridker, P. M., and Maseri, A., Inflammation and atherosclerosis. Circulation., 105, 1135–1143 (2000).

    Article  Google Scholar 

  • Lipsky, P. E. and Ziff, M., Inhibition of antigen-and mitogen-induced human lymphocyte proliferation by gold compounds. J. Clin. Invest., 59, 455–466 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Majumder, N., Dey, R., Mathur, R. K., Datta, S., Maitra, M., Ghosh, S., Saha, B., and Majumdar, S., An unusual pro-inflammatory role of interleukin-10 induced by arabinosylated lipoarabinomannan in murine peritoneal macrophages. Glycoconj, J., 23, 675–686 (2006).

    Article  CAS  Google Scholar 

  • Nathan, C., Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest., 100, 2417–2423 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Nishimoto, N., Cytokine signal regulation and autoimmune disorders. Autoimmunity., 38, 359–367 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Peters-Golden, M. and Shelly, C., The oral gold compound auranofin triggers arachidonate release and cyclooxygenase metabolism in the alveolar macrophage. Prostaglandins., 36, 773–786 (1988).

    Article  PubMed  CAS  Google Scholar 

  • Robinson, D. R., Tashjian, A. H. Jr., and Levine, L., Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J. Clin Invest., 56, 1181–1188 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Sano, H., Hla, T., Maier, J. A., Crofford, L. J., Case, J. P., Maciag, T., and Wilder, R. L., In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin Invest., 89, 97–108 (1992).

    Article  PubMed  CAS  Google Scholar 

  • Scheinberg, M. A., Santos, L. M., and Finkelstein, A. E., The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J. Rheumatol., 9, 366–369 (1982).

    PubMed  CAS  Google Scholar 

  • Seitz, M., Loetscher, P., Dewald, B., Towbin, H., Ceska, M., and Baggiolini, M., Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes-regulation by IFN-gamma and IL-4. J. Immunol., 52, 2060–2065 (1994).

    Google Scholar 

  • Siegle, I., Klein, T., Backman, J. T., Saal, J. G., Nusing, R. M., and Fritz, P., Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum., 41, 122–129 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Smith, W. L., Meade, E. A., and DeWitt, D. L., Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and-2. Ann NY Acad Sci., 18, 136–142 (1994).

    Article  Google Scholar 

  • Snyder, R. M., Mirabelli, C. K., and Crooke, S. T., The cellular pharmacology of auranofin. Semin Arthritis Rheum., 17, 71–80 (1987).

    Article  PubMed  CAS  Google Scholar 

  • Stuehr, D. J. and Nathan, C. F., Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169, 1543–1555 (1989).

    Article  PubMed  CAS  Google Scholar 

  • Taylor, D. J., Interleukin-4 (IL-4) induces down-modulation and shedding of the p55 tumor necrosis factor receptor and inhibits TNF alpha’s effect on rheumatoid synovial fibroblasts. Rheumatol Int., 14, 21–25 (1994).

    Article  PubMed  CAS  Google Scholar 

  • Tilg, H., Wilmer, A., Vogel, W., Herold, M., Nolchen, B., Judmaier, G., and Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology., 103, 264–274 (1997).

    Google Scholar 

  • Vane, J. R., Bakhle, Y. S., and Botting, R. M., Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol., 38, 97–120 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Vila-Del, Sol, V. and Fresno, M., Involvement of TNF and NF-{kappa}B in the transcriptional control of cyclooxygenase-2 expression by IFN-{gamma} in macrophages. J. Immunol., 174, 2825–2833 (2005).

    Google Scholar 

  • Yamada, M., Niki, H., Yamashita, M., Mue, S., and Ohuchi, K., Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J. Pharmacol. Exp. Ther., 281, 1005–1012 (1997).

    PubMed  CAS  Google Scholar 

  • Yamada, R., Sano, H., Hla, T., Hashiramoto, A., Fukui, W., Miyazaki, S., Kohno, M., Tsubouchi, Y., Kusaka, Y., and Kondo, M., Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. Eur J. Pharmacol., 385, 71–79 (1997).

    Article  Google Scholar 

  • Yamashita, M., Niki, H., Yamada, M., Watanabe-Kobayashi, M., Mue, S., and Ohuchi K., Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages. Eur J. Pharmacol., 325, 221–227 (1997).

    Article  PubMed  CAS  Google Scholar 

  • Zhong, B., Tajima, M., Takahara, H., Nochi, H., Tamoto, K., Tamura, N., bayashi, S., Tamura, Y., Ikeda, M., Akimoto, T., Yoshino, S., and Hashimoto, H., Inhibitory effect of mizoribine on matrix metalloproteinase-1 production in synovial fibroblasts and THP-1 macrophages. Mod. Rheumatol., 15, 264–268 (2005).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kyungjae Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, S., Kim, K., Kim, H. et al. Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. Arch. Pharm. Res. 31, 67–74 (2008). https://doi.org/10.1007/s12272-008-1122-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-008-1122-9

Key words

Navigation